BriaCell Therapeutics (NASDAQ:BCTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

BriaCell Therapeutics (NASDAQ:BCTX) had its target price lifted by equities researchers at HC Wainwright from $15.00 to $32.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

BriaCell Therapeutics Price Performance

Shares of NASDAQ:BCTX opened at $4.10 on Monday. The company’s 50-day moving average price is $8.95 and its two-hundred day moving average price is $10.37. BriaCell Therapeutics has a one year low of $3.92 and a one year high of $65.25. The stock has a market capitalization of $12.09 million, a PE ratio of -0.31 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last released its earnings results on Monday, December 16th. The company reported ($3.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($2.10). On average, analysts anticipate that BriaCell Therapeutics will post -15.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.